Galectin-3 coats the membrane of breast cells and makes a signature of tumours
Malara, Natalia Maria
Di Fabrizio, Enzo M.
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Material Science and Engineering Program
Physical Science and Engineering (PSE) Division
Permanent link to this recordhttp://hdl.handle.net/10754/563168
MetadataShow full item record
AbstractGalectin-3, β-galactoside-binding lectin, coats the membrane of most cancer cells and is involved in metastasis and endothelium recognition as well as in evading immune surveillance through killing of activated T cells. To flag galectin as a biomarker of tumours and metastasis, it is pivotal to understand the role of this protein in different tumours and at different stages. Breast tumours have an anomalous behaviour of the galectin-3 compared to other tumour cells. Herein, FACS sorting and galactoside based assays were used to investigate the role of galectin-3 in metastasis and metastatisation of breast cancer cells. Breast galectin fingerprint at the FACS displayed a higher amount in healthy cells, compared to metastatic cells. The microfluidic assay was able to isolate tumour and metastatic cells more than healthy breast cells. Investigation was performed on samples from patients with breast tumours at stage I and stage III whilst MCF7 and EPH-4 cells were used to perform preliminary investigations. The readout of the conditioned medium (from culturing of stage I cells) fingerprint by FACS evidenced high expression of free galectin. Analysis of the results established that the galectin coating the membrane, by galactoside recognition of the breast cells, and engaged by the cells to form protein-carbohydrate complexes inside the microfluidic assay, resembled the tumour signature of tumours in breast cells whilst the galectin free is independent of those mechanisms. © 2014 The Royal Society of Chemistry.
SponsorsThis work was partially supported by the project PON "Nuove strategie nanotecnologiche per la messa a punto di farmaci e presidi diagnostici diretti verso cellule cancerose circolanti.'' (cod. PON01_02782, CUP B71H11000870005), and the project FIRB "Rete Nazionale di Ricerca sulle Nanoscienze ItalNanoNet'' (cod. RBPR05JH2P_010, CUP B41J09000110005) granted to the nanotechnology laboratory of the Department of Experimental Medicine of the University of Magna Graecia of Catanzaro, the foundation "T. Campanella'' and RSA (ANASTE Calabria). The authors are grateful to Prof. Torella, Prof. Agosti, Prof. Fresta. Moreover, the authors are grateful to all patients and relatives involved in this study.
PublisherRoyal Society of Chemistry (RSC)
- Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
- Authors: Moiseeva EV, Rapoport EM, Bovin NV, Miroshnikov AI, Chaadaeva AV, Krasilshschikova MS, Bojenko VK, Bijleveld C, van Dijk JE, Den Otter W
- Issue date: 2005 Jun
- Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells.
- Authors: Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP
- Issue date: 2000 May 15
- Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer.
- Authors: Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, Hirashima M
- Issue date: 2006 Sep-Oct
- Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
- Authors: Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, Hirashima M
- Issue date: 2005 Apr 15
- Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3.
- Authors: Bresalier RS, Byrd JC, Wang L, Raz A
- Issue date: 1996 Oct 1